``The Early Show'' on CBS Previews Lifeline BioTechnologies' First Warning System.

Business Editors & Health Writers

NEW YORK--(BUSINESS WIRE)--Dec. 21, 1999

Examining future technologies in breast cancer detection during "The Early Show" on CBS this morning brought Lifeline BioTechnologies' First Warning(TM) system into the spotlight.

Dr. Emily Senay reported on the latest advances and explained the ability of the First Warning technology to determine breast cancer risk in women at much earlier stages than current methods.

This breakthrough technology developed by Lifeline BioTechnologies has demonstrated in early clinical trials the diagnostic ability to detect breast cancer three to five years earlier than currently available techniques such as mammography.

The noninvasive test known as First Warning demonstrates great promise in detecting formation of extremely early-stage breast lesions, particularly in younger women. Thanks in part to new detection technology like this, modern breast cancer survival rates continue to improve.

No practical noninvasive high-risk marker exists today that can effectively cope with the problem of breast cancer. Although early detection and prompt treatment are the stock phrases that epitomize current efforts toward the clinical control and cure of breast cancer, unfortunately there is no method available to the medical community that can fulfill this promise.

Presently, the medical community cannot identify women at the highest risk for breast cancer development by noninvasive physiological grading.

First Warning may be the only product under development that can fill this niche economically and practically. With classic risk factors, such as family history and age at first full-term pregnancy, found in only 20 percent of the patients diagnosed with breast cancer, the number of women who go undetected is large.

Alarming statistics indicate that 80 percent of all women who eventually develop breast cancer had no warning whatsoever that they were at risk and 45 percent of those affected in the United States will die. Lifeline BioTechnologies is working at reducing these numbers with the First Warning system.

For more information about Lifeline BioTechnologies, go to the company's Web site at www.lbti.com or e-mail [e-mail].

Safe-harbor statement under the Private Securities Litigation Reform Act of 1995: The statements contained herein that are not historical are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including but not limited to certain delays beyond the company's control with respect to market acceptance of new technologies or products, delays in testing and evaluation of products, federal regulatory approval and other risks.